Moderna is down 80% from its 52-week high as ... like potential approval of a next-gen COVID vaccine and a possible label expansion for the RSV vaccine due in 2025. An opportunity for an early ...

This includes more than $3.0 billion in Spikevax ... label extension study. The Company began generating registrational trial data in 2024. Methylmalonic acidemia (MMA) therapeutic ...

This includes more than $3.0 billion in Spikevax® sales ... to continue on the open label extension study. The Company began generating registrational trial data in 2024. Methylmalonic acidemia (MMA) ...

Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...